Adaptive Biotechnologies(US:ADPT)2025-05-01 20:52Financial Performance - Total revenue for Q1 2025 was $52.4 million, a 25% increase year-over-year compared to $41.9 million in Q1 2024[23] - MRD (Minimal Residual Disease) revenue reached $43.7 million in Q1 2025, representing a 34% year-over-year growth[8, 23] - Excluding milestones, MRD revenue grew by 39% year-over-year[8] - Immune Medicine revenue was $8.7 million in Q1 2025, a 6% decrease compared to Q1 2024[23] - Total operating expenses decreased by 9% year-over-year[8, 23] - The company's Q1 2025 cash burn was approximately $23 million, a 38% reduction compared to Q1 2024[8] - The company had a strong cash position with approximately $233 million in cash, cash equivalents, and marketable securities as of March 31, 2025[8] MRD Business - Clinical testing revenue increased by 55% year-over-year in Q1 2025[11] - clonoSEQ US volume reached 22,368 in Q1 2025[12] - Ordering HCPs (Healthcare Professionals) increased by 31% year-over-year in Q1 2025[12] Guidance - The company increased its FY 2025 MRD revenue guidance to between $180 million and $190 million, compared to the previous guidance of $175 million to $185 million[26]